Senator scrutinizes pharma links on government pain panel

Senator scrutinizes pharma links on government pain panel

By Associated Press  |  February 08, 2016

Sen. Ron Wyden says he has "a number of concerns" about how panelists were selected and screened for an advisory panel on pain issues that includes government experts, outside academics and patient advocates.

Could Massachusetts have the tool to fix high drug costs?

Could Massachusetts have the tool to fix high drug costs?

By Lisa Schencker  |  February 03, 2016

There might be another tool in the battle against high drug costs: state consumer protection laws. A potential lawsuit in Massachusetts against drugmaker Gilead over its costly hepatitis C drugs could, if successful, forge a new path for states working to combat the high costs of certain drugs.

Drug developer sets Michigan record by raising $62 million

By Tom Henderson, Crain's Detroit Business  |  January 05, 2016

Ann Arbor, Mich.-based Millendo Therapeutics announced Tuesday morning it has raised a venture capital round of $62 million, the largest VC round for a drug development company in Michigan history.

New tax inversion rules put damper on pending Pfizer-Allergan deal

By Beth Kutscher  |  November 20, 2015

An expected deal between pharmaceutical giants Pfizer and Allergan that's expected to be worth up to $380 a share could become less lucrative under new U.S. Treasury rules designed to diminish the benefits of cross-border transactions.

Providers and insurers must help ACOs reach their goals

By Modern Healthcare  |  October 17, 2015

Providers and insurers need to do a better job of reaching patients and employers to help private accountable care organizations achieve lower costs and higher quality, according to physician executives at four large health insurance companies.

Data show Genentech paid the most to providers

By Art Golab and Michael Sandler  |  July 04, 2015

Genentech, the maker of Avastin and other pricey cancer drugs, paid physicians and teaching hospitals more than any other drug or device company did in 2014, according to data published last week on the CMS' Open Payments website.

Medicare Part D data show big spending on brand names

By Bob Herman  |  May 02, 2015

Medicare shelled out more than $103 billion on prescription drugs in 2013, raising questions about why the government pays so much for brand-name pharmaceuticals and how physicians prescribe drugs for their patients.

Modern Healthcare Daily

Award winning coverage of healthcare business and policy news.

The Modern Healthcare app includes a personalized home screen, strong search functionality and immediate downloads from the industry's leading healthcare media brand.